The device can be rapidly prepared by connecting a bag of infusate and priming the pump. Primary patency and secondary patency were 100% and 100%. The ThromCat XT (Kensey Nash, Exton, PA, USA) is a 5.5 F device compatible with 7 F guide catheters, is fully disposable, and consists of a 150-cm catheter attached to a control unit, a power line, an infusate line, and an extraction line (Fig. No patients died, no restenosis was detected during follow-up, and no reintervention were performed. Mean follow-up was 24 months (range, 2-36 months). New brain lesions were identified in two patients by diffusion-weighted magnetic resonance imaging within the first 24 hours, one silent (in the first subgroup) and one in the epileptic patient. New cerebral events did not occur after the operative procedure and within the first 30 days. Two important bradycardias were registered during the postdilation period (one in the first subgroup and one in the second). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. In the second group, immediate technical success was 100% one epileptic fit with residual neurologic deficit on day 1 occurred, but no minor or major stroke. is an innovative medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard(TM). The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Two patients presented with a transient ischemic attack in the perioperative period, and the lesions were all predilated. TEL AVIV, Israel, /PRNewswire/ - InspireMD, Inc. InspireMD Inc is the United States based medical device company. In the first subgroup, three patients had a technical failure and were treated with CAS with another carotid stent. CGuard Carotid Stent System is indicated for improving. In this study, 39 patients (74.6 years 38.8% female 2.5% symptomatic) underwent CAS procedures. Using their MicroNet technology they have developed CGuard and MGuard Embolic Protection System. Journal of Vascular Surgery Cases, Innovations and Techniques.Journal of Vascular Surgery: Venous and Lymphatic The goal of this study is to demonstrate the superiority of the MGuard stent over commercially-approved bare-metal (BMS) /drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the treatment of acute ST-elevation myocardial infarction (STEMI).In the MASTER trial, a total of 433 patients with STEMI presenting within 12 hours of symptom onset undergoing percutaneous coronary intervention (PCI) were randomized at 50 sites in nine countries to the MGuard EPS (n = 217) or commercially available bare metal or drug-eluting stents (n = 216). These findings corroborate the previously announced 30-day results showing that all-cause mortality with MGuard EPS was lower than bare metal and drug-eluting stents used as a control (0 percent vs. Contact a supplier or the parent company directly to get a quote. Secondary endpoint clinical outcomes continue to show a lower mortality rate with MGuard EPS compared to control (0.5 percent vs. Find out all of the information about the InspireMD product: coronary stent MGuard Prime. Between May 2015 and May 2018, we performed a total of 39 consecutive carotid artery stenting (CAS) procedures with the InspireMD CGuard stent 13 were. The MASTER trial achieved its primary endpoint (p value = 0.008), in complete ST-segment resolution at 60 to 90 minutes post-procedure (a strong predictor of mortality). survival.3-6 The MGuard embolic protection stent (InspireMD Ltd. croembolization (eg the MGuard stent) in patients with acute coronary syndromes does. With its micro-net mesh sleeve, MGuard EPS prevents unstable arterial plaque and thrombus (clots) that cause heart attack blockage from breaking off and exacerbating damage. In large thrombus lesions, the MGuard stent was more effective than control stents in. The MGuard stent (InspireMD, Tel Aviv, Israel) was designed as a. announced new six-month results from the MASTER ( MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard embolic protection stent (EPS) outperformed bare metal stents and drug-eluting stents in all-cause mortality in ST-segment elevation myocardial infarction (STEMI) patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |